1. Home
  2. SPRO vs INMB Comparison

SPRO vs INMB Comparison

Compare SPRO & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Logo INmune Bio Inc.

INMB

INmune Bio Inc.

HOLD

Current Price

$2.40

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
INMB
Founded
2013
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.6M
57.9M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
SPRO
INMB
Price
$1.21
$2.40
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.40
AVG Volume (30 Days)
607.0K
358.8K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
11.85
EPS
N/A
N/A
Revenue
$66,802,000.00
$50,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
257.14
52 Week Low
$1.08
$1.09
52 Week High
$3.08
$2.50

Technical Indicators

Market Signals
Indicator
SPRO
INMB
Relative Strength Index (RSI) 34.07 70.66
Support Level $1.18 $1.16
Resistance Level $1.29 N/A
Average True Range (ATR) 0.05 0.12
MACD 0.03 0.03
Stochastic Oscillator 16.00 83.84

Price Performance

Historical Comparison
SPRO
INMB

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About INMB INmune Bio Inc.

INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.

Share on Social Networks: